Navigation Links
Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
Date:3/7/2012

ncludes six months after the final surgery.

About Neuralstem
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD).  Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please visit www.neuralstem.com and connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
2. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
3. Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri
4. North Dakota Pharmacists and Medication Management Systems Partner to Deliver Quality MTM Services to Patients With Diabetes
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CSL Behrings Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients
7. IDIS Opens New American Office in Response to Industrys Growing Need for Pre-Launch Named Patient Programs
8. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
9. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
10. With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients
11. Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Aug. 7 SyntheMed, Inc. (OTC Bulletin Board: SYMD), ... of anti-adhesion products, announced today that REPEL-CV Bioresorbable Adhesion ... National Association for Children,s Heart Disorders, Inc. Michelle L. ... to inform parents of children with congenital heart defects ...
... , BOTHELL, Wash., Aug. 7 SCOLR Pharma, ... for the three and six months ended June 30, 2009. ... President and CEO, said, "We continue to advance discussions with a ... potential partners have been committing resources to due diligence and preliminary ...
... EXTON, Pa., Aug. 7 Kensey Nash Corporation today ... distribution rights, along with the trademark, inventory and other ... line. Under the terms of the agreement, the Company ... OsseoFit distribution agreement. Pursuant to the agreement, following a ...
Cached Biology Technology:REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... inexpensive land along coastlines for vacation homes and tourist hotels. ... that threatens the very coral reefs attracting tourists in the ... Research Institute and colleagues find that bacteria on coral reefs ... in seawater increases. , "I set up a seawater system ...
... Garvan Institute, in collaboration with Spanish scientists, have formulated ... normal growth controls, which may have far-reaching implications for ... found large regions of DNA are 'switched off' in ... the Garvan Institute, says: "These large regions ?referred to ...
... multifaceted study involving the Kuna Indians of Panama, ... chemical compound that is, in part, responsible, for ... chocolate products. , The researchers, who are from ... of Duesseldorf, Germany; and Harvard Medical School, hope ...
Cached Biology News:Cancer cells suppress large regions of DNA by a reversible process that can be tackled 2Heart-healthy compound in chocolate identified 2
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
...
... Materials for 15-20 enhancements when used as directed, ... Enhancement System is designed to amplify the desired signal ... for evaluating proteins with low expression., ... to blocking the membrane; 1x solution; 250 ml, ...
Applications: Western blotting ...
Biology Products: